MedTrace Logo

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

NCT04459078 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2022-12-02

No results posted yet for this study

Summary

This study is a single arm, open label, national multicenter study, to explore the efficacy and safety of the combination of Camrelizumab, apatinib and albumin paclitaxel in advanced untreated EGFR Wild Type and ALK-negative Lung Adenocarcinoma. The study does not consider PD-L1 expression, but tumor samples need to be explored by PD-L1 detection and other exploratory analysis.

Conditions

  • Adenocarcinoma of the Lung

Interventions

DRUG

Camrelizumab

Intravenous administration of (200mg/3weeks)

DRUG

Albumin Paclitacxel

intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles)

DRUG

Apatinib

Patients will be given oral of Apatinib (250mg Qd po for 5 days, take rest for 2 days every week)

Sponsors & Collaborators

  • Suzhou Sheng Diya Biomedical Co., Ltd.

    collaborator UNKNOWN

  • Hunan Cancer Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-26
Primary Completion
2023-05-15
Completion
2023-07-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04459078 on ClinicalTrials.gov